



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56, §1.97, AND §1.98

PTO-1449 FORM (MODIFIED)

SHEET 1 OF 1

ATTORNEY DOCKET NO.

PP20426.003

SERIAL NO.

10/814,480

APPLICANTS:

Nicholas M. Valiante

EXAMINER:

Yong Soo

FILING DATE:

March 29, 2004

CONFIRMATION NO.

9427

GROUP ART UNIT:

1617

U.S. PATENT DOCUMENTS

Ex'r Initial	Ref. No.	Document No.	Date	Name	Class	Subclass	Filed
YLC	A1	6,211,177	3 April 2001	Sperl et al.			
	A2	6,248,771	19 June 2001	Shenoy et al.			
	A3	6,399,603	4 June 2002	Jacobs et al.			
	A4	6,417,194	9 July 2002	Fox et al.			

FOREIGN PATENT DOCUMENTS

Ex'r Initial	Ref. No.	Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
YLC	B1	WO 00/62778 A	26 October 2000	PCT			
	B2	WO 01/66539 A	13 September 2001	PCT			
	B3	WO04/985425A1	7 October 2004	PCT			
	B4	WO02/42273A2	30 May 2002	PCT			
	B5	WO02/44156A2	6 June 2002	PCT			
	B6	WO02/076960A1	3 October 2002	PCT			
	B7	WO02/094808A1	28 November 2002	PCT			
	B8	WO03/082272A1	9 October 2003	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Ex'r Initial	Ref. No.	Description
YLC	C1	
	C2	
	C3	
	C4	

EXAMINER'S SIGNATURE

DATE CONSIDERED

10/20/05

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609.
Line through citation if not in conformance and not considered.
Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).



FORM PTO-1449 (Modified)	U.S. Dept. of Commerce Patent and Trademark Office	Atty. Docket No.: 20426.003	Serial No.: 10/814,480
INFORMATION DISCLOSURE CITATION		Applicants: Valiante <u>et al.</u>	
(Use several sheets if necessary)		Filing Date: March 29, 2004	Group: to be assigned

U.S. PATENT DOCUMENTS

*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
YL	AA	2002/0022624	02/21/02	Dinnell <u>et al.</u>			

FOREIGN PATENT DOCUMENTS

		Document Number	Publ. Date	Country	Class	Subclass	Trans-Yes	lation No
YL	BA	WO 00/12074	03/09/00	PCT				
	BB	WO 02/22598	03/21/02	PCT				
	BC	WO 00/76505	12/21/00	PCT				
	BD	WO 01/64668	09/07/01	PCT			(abstract only)	
	BE	WO 02/090375	05/02/01	PCT				
	BF	WO 02/083624	10/24/02	PCT				
	BG	WO 03/000694	01/03/03	PCT				
↓	BH	WO 00/59904	10/12/00	PCT				

OTHER CITATIONS (Including Author, Title, Date, Pertinent Pages, Etc.)

YL	AA	Sato <u>et al.</u> , "Characteristics of Antitumor Activity of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]- . . ." <u>Cancer Letters</u> 91:1-9, 1995
	AB	Oyaizu <u>et al.</u> , "Inhibition of CD4 Cross-Linking-Induced Lymphocytes Apoptosis by Vesnarinone as a Novel Immunomodulating Agent . . ." <u>Blood</u> 87(6):2361-2368, March 15, 1996
	AC	Toldy <u>et al.</u> , "3,4,5-Trimethoxybenzoyl derivative, Eine Neue Verbindungsgruppe Mit Antiulzerogener Wirkung" <u>Acta Chimica Academiae Scientiarum Hungaricae Tomus</u> 49(3):265-286, 1966
	AD	Sato <u>et al.</u> , "Induction of Tumour Differentiation and Apoptosis and Le ¹ Antigen Expression in Treatment with Differentiation-Inducing Agent, Vesnarinone, of a Patient with Salivary Adenoid Cystic Carcinoma" <u>Apoptosis</u> 2:106-113, 1997
	AE	Petigara <u>et al.</u> , "Synthesis and Central Nervous System Depressant Activity of New Piperazine Derivatives" 11:332-336, March 1, 1968
↓	AF	Yamaguchi, "Vesnarinone Inhibits Growth of Large Cell Lung Cancer Cell Lines via Induction of Apoptosis" <u>Med. J. Kagoshima Univ.</u> 51(4):67-75, February, 2000
Examiner	Yong Chong	
Date Considered	10/20/05	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.